<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-18T00:35:53Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:11351/11549" metadataPrefix="oai_dc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:11351/11549</identifier><datestamp>2025-10-24T10:16:11Z</datestamp><setSpec>com_2072_378070</setSpec><setSpec>com_2072_378040</setSpec><setSpec>col_2072_378092</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>Risk prediction of major cardiac adverse events and all-cause death following covid-19 hospitalization at one year follow-up: The HOPE-2 score</dc:title>
   <dc:creator>Becerra Muñoz, Víctor Manuel</dc:creator>
   <dc:creator>Santoro, Francesco</dc:creator>
   <dc:creator>Nuñez Gil, Ivan Javier</dc:creator>
   <dc:creator>Viana-Llamas, María C.</dc:creator>
   <dc:creator>Alfonso, Emilio</dc:creator>
   <dc:creator>Uribarri, Aitor</dc:creator>
   <dc:contributor>Institut Català de la Salut</dc:contributor>
   <dc:contributor>[Santoro F] Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. [Núñez-Gil IJ] Hospital Clinico San Carlos, Madrid, Spain. [Viana-Llamas MC] Hospital Universitario Guadalajara, Guadalajara, Spain. [Alfonso-Rodríguez E] Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain. [Uribarri A] Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Becerra-Muñoz VM] Servicio de Cardiología, Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain</dc:contributor>
   <dc:contributor>Vall d'Hebron Barcelona Hospital Campus</dc:contributor>
   <dc:subject>COVID-19 (Malaltia)</dc:subject>
   <dc:subject>Avaluació del risc</dc:subject>
   <dc:subject>Cor - Malalties - Factors de risc</dc:subject>
   <dc:subject>DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections</dc:subject>
   <dc:subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Assessment</dc:subject>
   <dc:subject>DISEASES::Cardiovascular Diseases</dc:subject>
   <dc:subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Patient Care::Hospitalization</dc:subject>
   <dc:subject>ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus</dc:subject>
   <dc:subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::evaluación de riesgos</dc:subject>
   <dc:subject>ENFERMEDADES::enfermedades cardiovasculares</dc:subject>
   <dc:subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::asistencia al paciente::hospitalización</dc:subject>
   <dc:description>COVID-19; Long-COVID; Prognostic score</dc:description>
   <dc:description>COVID-19; COVID llarg; Puntuació pronòstica</dc:description>
   <dc:description>COVID-19; COVID largo; Puntuación pronóstica</dc:description>
   <dc:description>Background&#xd;
Long-term consequences of COVID-19 are still partly known.&#xd;
Aim of the study&#xd;
To derive a clinical score for risk prediction of long-term major cardiac adverse events (MACE) and all cause death in COVID-19 hospitalized patients.&#xd;
Methods&#xd;
2573 consecutive patients were enrolled in a multicenter, international registry (HOPE-2) from January 2020 to April 2021 and identified as the derivation cohort. Five hundred and twenty-six patients from the Cardio-Covid-Italy registry were considered as external validation cohort. A long-term prognostic risk score for MACE and all cause death was derived from a multivariable regression model.&#xd;
Results&#xd;
Out of 2573 patients enrolled in the HOPE-2 registry, 1481 (58 %) were male, with mean age of 60±16 years. At long-term follow-up, the overall rate of patients affected by MACE and/or all cause death was 7.8 %. After multivariable regression analysis, independent predictors of MACE and all cause death were identified. The HOPE-2 prognostic score was therefore calculated by giving: 1–4 points for age class (&lt;65 years, 65–74, 75–84, ≥85), 3 points for history of cardiovascular disease, 1 point for hypertension, 3 points for increased troponin serum levels at admission and 2 points for acute renal failure during hospitalization. Score accuracy at ROC curve analysis was 0.79 (0.74 at external validation).&#xd;
Stratification into 3 risk groups (&lt;3, 3–6, >6 points) classified patients into low, intermediate and high risk. The observed MACE and all-cause death rates were 1.9 %, 9.4 % and 26.3 % for low- intermediate and high-risk patients, respectively (Log-rank test p &lt; 0.01).&#xd;
Conclusions&#xd;
The HOPE-2 prognostic score may be useful for long-term risk stratification in patients with previous COVID-19 hospitalization. High-risk patients may require a strict follow-up.</dc:description>
   <dc:date>2024-06-05T06:31:13Z</dc:date>
   <dc:date>2024-06-05T06:31:13Z</dc:date>
   <dc:date>2024-06</dc:date>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
   <dc:identifier>Santoro F, Núñez-Gil IJ, Viana-Llamas MC, Alfonso-Rodríguez E, Uribarri A, Becerra-Muñoz VM, et al. Risk prediction of major cardiac adverse events and all-cause death following covid-19 hospitalization at one year follow-up: The HOPE-2 score. Eur J Intern Med. 2024 Mar;124:108–14.</dc:identifier>
   <dc:identifier>0953-6205</dc:identifier>
   <dc:identifier>https://hdl.handle.net/11351/11549</dc:identifier>
   <dc:identifier>10.1016/j.ejim.2024.03.002</dc:identifier>
   <dc:identifier>38472045</dc:identifier>
   <dc:identifier>http://hdl.handle.net/11351/11549</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>European Journal of Internal Medicine;124</dc:relation>
   <dc:relation>https://doi.org/10.1016/j.ejim.2024.03.002</dc:relation>
   <dc:rights>Attribution-NonCommercial-NoDerivatives 4.0 International</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:format>application/pdf</dc:format>
   <dc:publisher>Elsevier</dc:publisher>
   <dc:source>Scientia</dc:source>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>